Trial reportContemporary clinical trials2016
An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder.
Trial report in Contemporary clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Intranasal Oxytocin for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled Multisite Trial Assessing Efficacy and Safety.Alcohol, clinical & experimental research · 2026Trial
- Reductions in cigarette and cannabis use during a randomized clinical trial for alcohol use disorder.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Trial
- Variations in alcohol craving and negative mood during a clinical trial of ibudilast for alcohol use disorder.Alcohol, clinical & experimental research · 2025Trial
- A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Identifying responders to gabapentin for the treatment of alcohol use disorder: an exploratory machine learning approach.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Trial
- Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Trial
- Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorder.Journal of psychiatric research · 2024Trial
- Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder.Drug and alcohol dependence · 2024Trial
- Effects of Internet-Based Cognitive Behavioral Therapy for Harmful Alcohol Use and Alcohol Dependence as Self-help or With Therapist Guidance: Three-Armed Randomized Trial.Journal of medical Internet research · 2021Trial
- Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.Alcoholism, clinical and experimental research · 2019Trial
- Oxytocin as a treatment for alcohol use disorder and heavy drinking: A narrative review.Experimental and clinical psychopharmacology · 2024Review
- Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.Clinics in liver disease · 2024Review
- Efficacy of the Unified Protocol for the treatment of comorbid alcohol use and anxiety disorders: Study protocol and methods.Contemporary clinical trials · 2021Article
- The future of translational research on alcohol use disorder.Addiction biology · 2021Article
- Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.Trials · 2020Article
- Advances in the science and treatment of alcohol use disorder.Science advances · 2019Review
- State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.The American journal of drug and alcohol abuse · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Placebo-controlled pharmacotherapy trials for alcohol use disorder (AUD) require an active behavioral platform to avoid putting participants at risk for untreated AUD and to better assess the effectiveness of the medication. Therapist-delivered platforms (TDP) can be costly and present a risk to study design because of the variability in therapist fidelity. Take Control is a novel computer-delivered behavioral platform developed for use in pharmacotherapy trials sponsored by the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG). This behavioral platform was developed with the goal of reducing trial implementation costs and limiting potential bias introduced by therapists providing TDP. This exploratory study is the first to compare Take Control with TDP on measures related to placebo response rate, medication adherence, and participant retention. Data were drawn from the placebo arms of four multisite, double-blind, randomized controlled trials (RCT) for AUD conducted by NCIG from 2007 to 2015. Data were compared from subjects receiving TDP (n=156) in two RCTs and Take Control (n=155) in another two RCTs. Placebo response rate, as represented by weekly percentage of heavy drinking days, was similar between groups. Subjects who received Take Control had a higher rate of medication adherence than those who received TDP. Subject retention was not significantly different between groups. The findings suggest that Take Control is comparable to TDP on measures of retention, medication adherence, and placebo response. Additional research is needed to evaluate Take Control directly against TDPs in a randomized trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.